Details for Patent: 7,465,437

Title:	Delivery of anti-migraine compounds through an inhalation route
Abstract:	The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing lidocaine, verapamil, diltiazem, isometheptene, or lisuride that are used in inhalation therapy. In a method aspect of the present invention, lidocaine, verapamil, diltiazem, isometheptene, or lisuride is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of lidocaine, verapamil, diltiazem, isometheptene, or lisuride, on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering lidocaine, verapamil, diltiazem, isometheptene, or lisuride through an inhalation route is provided which comprises: a) a thin coating of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride composition and b) a device for dispensing said thin coating as a condensation aerosol.
Inventor(s):	Rabinowitz; Joshua D (Princeton, NJ), Zaffaroni; Alejandro C (Atherton, CA)
Assignee:	Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Filing Date:	Jun 16, 2006
Application Number:	11/454,573
Claims:	1. A condensation aerosol for delivery of lidocaine formed by heating a composition containing lidocaine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of lidocaine and less than 5 percent by weight of lidocaine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 2. The condensation aerosol according to claim 1, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 3. The condensation aerosol according to claim 1 or claim 2, wherein the geometric standard deviation around the MMAD is less than 3.0. 4. A condensation aerosol for delivery of verapamil formed by heating a composition containing verapamil coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of verapamil and less than 5 percent by weight of verapamil degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 5. The condensation aerosol according to claim 4, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 6. The condensation aerosol according to claim 4 or claim 5, wherein the geometric standard deviation around the MMAD is less than 3.0. 7. A condensation aerosol for delivery of diltiazem formed by heating a composition containing diltiazem coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of diltiazem and less than 5 percent by weight of diltiazem degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 8. The condensation aerosol according to claim 7, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 9. The condensation aerosol according to claim 7 or claim 8, wherein the geometric standard deviation around the MMAD is less than 3.0. 10. A condensation aerosol for delivery of isometheptene formed by heating a composition containing isometheptene coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of isometheptene and less than 5 percent by weight of isometheptene degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 11. The condensation aerosol according to claim 10, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 12. The condensation aerosol according to claim 10 or claim 11, wherein the geometric standard deviation around the MMAD is less than 3.0. 13. A condensation aerosol for delivery of lisuride by heating a composition containing lisuride coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of lisuride and less than 5 percent by weight of lisuride degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 14. The condensation aerosol according to claim 13, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 15. The condensation aerosol according to claim 13 or claim 14, wherein the geometric standard deviation around the MMAD is less than 3.0. 16. A method of forming a lidocaine containing aerosol comprising: (a) heating a composition containing lidocaine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of lidocaine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 17. The method according to claim 16, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 18. The method according to claim 17, wherein the coated composition comprises at least 10 percent by weight of lidocaine. 19. A method of forming a verapamil containing aerosol comprising: (a) heating a composition containing verapamil coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of verapamil degradation product, and the condensation aerosol has an MMAD of less than 5 microns. 20. The method according to claim 19, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 21. The method according to claim 20, wherein the coated composition comprises at least 10 percent by weight of verapamil. 22. A method of forming a diltiazem containing aerosol comprising: (a) heating a composition containing diltiazem coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of diltiazem degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 23. The method according to claim 22, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 24. The method according to claim 23, wherein the coated composition comprises at least 10 percent by weight of diltiazem. 25. A method of forming a isometheptene containing aerosol comprising: (a) heating a composition containing isometheptene coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of isometheptene degradation product, and the condensation aerosol has an MMAD of less than 5 microns. 26. The method according to claim 25, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 27. The method according to claim 26, wherein the coated composition comprises at least 10 percent by weight of isometheptene. 28. A method of forming a lisuride containing aerosol comprising: (a) heating a composition containing lisuride coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of lisuride degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 29. The method according to claim 28, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 30. The method according to claim 29, wherein the coated composition comprises at least 10 percent by weight of lisuride. 31. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of lidocaine, verapamil, diltiazem, isometheptene, and lisuride, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 32. The method according to claim 31, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 33. The method according to claim 32, wherein the coated composition comprises at least 10 percent by weight of the drug. 34. A method of forming a drug containing aerosol comprising: (a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of lidocaine, verapamil, diltiazem, isometheptene, and lisuride, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 35. The method according to claim 34, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 36. The method according to claim 35, wherein the coated composition comprises at least 10 percent by weight of the salt form of the drug. 37. The condensation aerosol according to claim 2, wherein the condensing comprises allowing the vapor to cool. 38. The condensation aerosol according to claim 5, wherein the condensing comprises allowing the vapor to cool. 39. The condensation aerosol according to claim 8, wherein the condensing comprises allowing the vapor to cool. 40. The condensation aerosol according to claim 11, wherein the condensing comprises allowing the vapor to cool. 41. The condensation aerosol according to claim 14, wherein the condensing comprises allowing the vapor to cool. 42. The method according to claim 17, wherein the condensing comprises allowing the vapor to cool. 43. The method according to claim 20, wherein the condensing comprises allowing the vapor to cool. 44. The method according to claim 23, wherein the condensing comprises allowing the vapor to cool. 45. The method according to claim 26, wherein the condensing comprises allowing the vapor to cool. 46. The method according to claim 29, wherein the condensing comprises allowing the vapor to cool. 47. The method according to claim 32, wherein the condensing comprises allowing the vapor to cool. 48. The method according to claim 35, wherein the condensing comprises allowing the vapor to cool. 49. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of lidocaine, verapamil, diltiazem, isometheptene, and lisuride, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 50. The method according to claim 49, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 51. The method according to claim 50, wherein the condensation aerosol is formed at a rate greater than 0.75 mg/second. 52. The method according to claim 51, wherein the condensation aerosol is formed at a rate greater than 1 mg/second. 53. The method according to claim 52, wherein the condensation aerosol is formed at a rate greater than 2 mg/second. 54. The method according to claim 49, wherein the condensing comprises allowing the vapor to cool.